Iowa State and 1 UNC

930 Views | 12 Replies | Last: 1 yr ago by Quinton
gobears20
How long do you want to ignore this user?
Staff
What's game so far

ISU leads 65-61
1:18 left
gobears20
How long do you want to ignore this user?
Staff
ISU leads 66-63
19.4 left
whitetrash
How long do you want to ignore this user?
Mr. "TooTightPolo" about to take down the Heels. Five minutes after UNC's kicker shanks a game tying FG in 2OT loss to NCSt.
gobears20
How long do you want to ignore this user?
Staff
Make Bacot a passer. He cannot pass without turning it over
DanaDane
How long do you want to ignore this user?
Caleb Grill can't miss. He's hit from all over the court.
gobears20
How long do you want to ignore this user?
Staff
ISU wins 70-65! Great win for the big 12!
DanaDane
How long do you want to ignore this user?
Down goes #1


IowaBear
How long do you want to ignore this user?
Isu defensively is rock solid! They'll be tough
contrario
How long do you want to ignore this user?
UH about to be the new #1. They haven't been tested so far and they only have a couple of games on their remaining schedule against ranked teams. They will very likely enter conference play undefeated and won't face much of a challenge in conference.
BUBradley
How long do you want to ignore this user?
Virginia plays Houston soon. We will see how they handle them.
broncko
How long do you want to ignore this user?
#22 Tenn 64
#3 Kansas 50
Quinton
How long do you want to ignore this user?
Looked good so far but haven't played anyone. Only team with D1 athletes was a heavily depleted Oregon. They didn't look that great and struggled to rebound and finish at the rim. Oregon is terrible so far this year.

Still wait and see with them. And as you say play one of the worst schedules in the country for a high level team. Play three teams with a pulse the entire year.. Gonzaga on steroids situation.
Quinton
How long do you want to ignore this user?
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.